sublingual tirzepatide study Is delivery the future for GLP-1 agonists? Tirzepatide Oral Rapid Dissolve Sublingual
Description
Using the wrong one, or reading the wrong scale, can result in dramatically incorrect doses
doi:10.1007/s00125-023-05956-x Qureshi N, Wesolowicz L, Stievater T, Lin AT
Most patients lose 1020% of body weight with consistent use and provider guidance
Patients with genetic variants associated with increased appetite signaling or altered nutrient metabolism may be more prone to rapid weight loss and secondary telogen effluvium
Monitor micronutrient status Smaller meal volumes can reduce intake of key vitamins and minerals
U.S.-licensed clinicians on every prescription, no auto-approvals
